(3S)-N,N-dimethylpyrrolidine-3-carboxamide | 1033706-42-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S)-N,N-dimethylpyrrolidine-3-carboxamide
• CAS: 1033706-42-1
• 化学式: C₇H₁₄N₂O
• 分子量: 142.201
• InChiKey: XFLOKZZHINFHNW-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde 、 (3S)-N,N-dimethylpyrrolidine-3-carboxamide 、 三乙酰氧基硼氢化钠 在 甲醇 、 desired product 、 resultant residue 、 Si 、 二氯甲烷 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 22.0h， 以to afford 398 as a cream solid (50 mg, 38%)的产率得到(S)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)-N,N-dimethylpyrrolidine-3-carboxamide
  参考文献：
  名称：

  BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE

  摘要：

  公式I（Ia和Ib）化合物，其中（i）X1为N且X2为S，（ii）X1为CR7且X2为S，（iii）X1为N且X2为NR2，或（iv）X1为CR7且X2为O，包括立体异构体，互变异构体，代谢物和其药学上可接受的盐，用于抑制PI3K的δ异构体，并用于治疗由脂质激酶介导的疾病，如炎症，免疫和癌症。公开了使用公式I化合物的方法，用于哺乳动物细胞中的体外，体内和原位诊断，预防或治疗这种疾病或相关的病理条件。

  公开号：

  US20100305096A1
• 作为产物：
  描述：

  (S)-1-Boc-吡咯烷-3-甲酸 、 (S)-Pyrrolidine-3-carboxylic acid methyl-amide 生成 (3S)-N,N-dimethylpyrrolidine-3-carboxamide
  参考文献：
  名称：

  QUINAZOLINEDIONE DERIVATIVE

  摘要：

  本发明涉及公式（I）所表示的喹唑啉二酮衍生物或其药学上可接受的盐。

  公开号：

  US20150141400A1

文献信息

• Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
  申请人：Lehmann-Lintz Thorsten

  公开号：US20100197908A1

  公开（公告）日：2010-08-05

  The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R 1 , R 2 , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的化合物，其中基团和基团B、W、X、Y、Z、R1、R2的含义如权利要求书1所述。此外，本发明还涉及含有本发明中至少一种化合物的制药组合物。由于其MCH受体拮抗活性，本发明中的制药组合物适用于治疗代谢性疾病和/或饮食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。
• Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
  申请人：Genentech, Inc.

  公开号：US08173650B2

  公开（公告）日：2012-05-08

  Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I（Ia和Ib）化合物，其中（i）X1为N且X2为S，（ii）X1为CR7且X2为S，（iii）X1为N且X2为NR2，或（iv）X1为CR7且X2为O，包括立体异构体，互变异构体，代谢物和其药学上可接受的盐，对于抑制PI3K的δ异构体以及治疗由脂质激酶介导的疾病如炎症，免疫和癌症等有用。公开了使用Formula I化合物的方法，用于哺乳动物细胞中体外，体内和原位诊断，预防或治疗此类疾病或相关病理条件。
• CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY
  申请人：FOB Synthesis, Inc.

  公开号：EP2590978B1

  公开（公告）日：2017-09-20
• Carbapenem Antibacterials with Gram-Negative Activity
  申请人：FOB Synthesis, Inc.

  公开号：US20130172313A1

  公开（公告）日：2013-07-04

  The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
• PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20210353608A1

  公开（公告）日：2021-11-18

  The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R 1 , A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.